Abstract:
The present invention provides methods for validating results of a pre-implantation genetic screen. Methods of the invention increase the efficacy of the common PGS assay FAST-SeqS by taking advantage of single-nucleotide polymorphisms (SNPs) generated from the assay to confirm copy number calls, detect errors, identify samples, and recognize and identify sources of contamination. Methods of the invention increase the reliability of a PGS result, thereby making embryo selection more precise and improving outcomes of in vitro fertilization.

Description:
CROSS-REFERENCE TO RELATED APPLICATION 
       [0001]    This application claims the benefit of and priority to U.S. Provisional Patent Application Ser. No. 62/103,802, filed Jan. 15, 2015, the contents of which are incorporated herein by reference in their entirety. 
     
    
     FIELD OF THE INVENTION 
       [0002]    The invention generally relates to pre-natal genetic testing, and specifically to using SNPs to validate copy number, to identify the origin of a sample, or to detect contamination in the sample. 
       BACKGROUND 
       [0003]    When a woman has difficulty becoming pregnant, she may turn to in vitro fertilization (IVF). IVF involves removing one or more ova from a woman&#39;s ovary, fertilizing it and growing it in a laboratory, and implanting it into the uterus of the patient who desires to become pregnant. However, numerous difficulties with IVF exist. Successful pregnancies are only achieved in approximately 29% of cycles, and only about 22% result in live births. 
         [0004]    One way to increase the chance of a full term pregnancy is to undergo pre-implantation genetic screening (PGS). PGS involves assessing the chromosome copy number of embryos to screen out those that are aneuploid and are thus not good candidates for implantation. Aneuploidy is a condition in which the number of chromosomes is not an exact multiple of the haploid number (23 in humans). Most aneuploidies, such as trisomy and monosomy, are lethal to the fetus. Others, such as trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome), cause congenital defects, growth deficiencies, and intellectual disabilities in the child. PGS aims to avoid those problems by screening out aneuploid embryos from implantation. 
         [0005]    Existing methods of PGS involve analyzing read counts of DNA sequences on each chromosome to detect differences in copy number indicative of aneuploidy. However, analytical errors can lead to false positive aneuploidy calls. Additionally, read count alone cannot distinguish certain altered copy number states, including triploidy, haploidy, and uniparental disomy. 
       SUMMARY 
       [0006]    The present invention provides methods of validating the result of a pre-implantation genetic screen. Methods of the invention increase the efficacy of the PGS assay, FAST-SeqS, by taking advantage of single-nucleotide polymorphisms (SNPs) generated from the assay to confirm copy number calls, detect errors, identify samples, and recognize and identify sources of contamination. Methods of the invention increase the reliability of a PGS result, thereby making embryo selection more precise and improving outcomes of in vitro fertilization. 
         [0007]    In embodiments, the invention provides a method for validating a putative chromosome copy number in a genomic sample using SNPs captured by FAST-SeqS method. The SNPs are sequenced to determine allele fraction across various loci. The allele fraction can be compared to the chromosome copy numbers determined by FAST-SeqS method to determine if those copy numbers are valid. For example, a copy number indicating monosomy would be invalidated by the detection of a heterozygous SNP or SNPs on a particular chromosome. Alternatively, an allele fraction showing loss of heterozygosity may prove that a copy number indicating diploidy is actually haploid. Various other permutations are described below. 
         [0008]    In other embodiments of the invention, the SNPs amplified and sequenced in the FAST-SeqS method are utilized to generate unique DNA fingerprints, which help identify samples. DNA fingerprinting is useful for determining whether two embryos are siblings, whether two samples are from the same embryo, and whether the correct embryo was selected and implanted. It also is useful for confirming proper labeling and identification of samples during testing, thereby reducing the incidence of human error affecting IVF results. 
         [0009]    In another embodiment, SNPs can be used to detect human contamination in a sample by calling out allele fractions or other characteristics of the SNPs that fail to conform to an expected distribution. When sample contamination has occurred, the allelic pattern of the SNPs can be used to back out the fingerprint of the contaminating sample and identify the source of contamination. 
         [0010]    In embodiments, the SNP-based approach to calling chromosome copy numbers, DNA fingerprinting, and contamination detection can be used for other applications beyond PGS. The methods described herein are useful for cancer screening, forensics, paternity testing, screening for genetic disorders, monitoring cancer treatments, and many other uses as would be known in the art. 
         [0011]    In certain aspects, the invention provides a method for validating a putative chromosome copy number in a genomic sample. The method involves obtaining sequencing reads from a genomic sample amplified by FAST-SeqS; enumerating read counts from the sequencing reads; calculating putative chromosome copy numbers of the genomic sample based on the read counts; obtaining allele fractions for SNPs in a region covered by the sequencing reads; and comparing the allele fractions to the putative chromosome copy numbers to validate the putative chromosome copy numbers. 
         [0012]    In some embodiments of the method, the genomic sample is biopsied from an embryo. In some embodiments, the genomic sample comprises circulating cell-free fetal DNA, amniotic fluid, chorionic villus, fetal cells in maternal blood, trophoblasts, umbilical cord blood, tumor biopsy, or circulating tumor DNA. 
         [0013]    In embodiments, an allele fraction that is inconsistent with the putative chromosome copy number invalidates the putative chromosome copy number. A putative chromosome copy number of 1 may indicate monosomy; a putative chromosome copy number of 2 may indicate disomy; and a putative chromosome copy number of 3 may indicate trisomy. In embodiments, an allele fraction may indicate a genomic locus is homozygous or that a genomic locus is heterozygous. An allele fraction or set of allele fractions of 100% may indicate monosomy, whereas an allele fraction or set of allele fractions of 50% may indicate disomy. An allele fraction or set of allele fractions between 10% and 40% or between 60 and 90% may indicate trisomy or tetrasomy. A putative chromosome copy number of 2 combined with allele fractions inconsistent with diploidy may indicate triploidy, haploidy, or isodisomic uniparental disomy. 
         [0014]    In some embodiments, the method further involves identifying allele fractions that deviate from an expected allele fraction by more than a threshold amount. The threshold may be, for example, 10% or 20%. In embodiments, the method may involve diagnosing trisomy 21, trisomy 18, trisomy 13, or another aneuploidy condition. 
         [0015]    In other aspects of the invention, a method is provided for validating a putative chromosome copy number in a genomic sample. The method involves obtaining putative chromosome copy numbers for a genomic sample, the copy numbers calculated from sequence read counts of FAST-SeqS-amplified DNA; obtaining allele fractions of SNPs in the genomic sample, the SNPs sequenced from FAST-SeqS-amplified DNA; comparing the allele fractions to the putative chromosome copy numbers; and determining whether the putative chromosome copy numbers are consistent with the allele fractions. 
         [0016]    In certain embodiments, the genomic sample is biopsied from an embryo. The genomic sample may include circulating cell-free fetal DNA, amniotic fluid, chorionic villus, fetal cells in maternal blood, trophoblasts, umbilical cord blood, tumor biopsy, or circulating tumor DNA. 
         [0017]    In embodiments, an allele fraction that is inconsistent with the putative chromosome copy number invalidates the putative chromosome copy number. A putative chromosome copy number of 1 may indicate monosomy; a putative chromosome copy number of 2 may indicate disomy; and a putative chromosome copy number of 3 may indicate trisomy. In embodiments, an allele fraction may indicate a genomic locus is homozygous or that a genomic locus is heterozygous. An allele fraction or set of allele fractions of 100% may indicate monosomy, whereas an allele fraction or set of allele fractions of 50% may indicate disomy. An allele fraction or set of allele fractions between 10% and 40% or between 60 and 90% may indicate trisomy or tetrasomy. A putative chromosome copy number of 2 combined with allele fractions inconsistent with diploidy may indicate triploidy, haploidy, or isodisomic uniparental disomy. 
         [0018]    In some embodiments, the method further involves identifying allele fractions that deviate from an expected allele fraction by more than a threshold amount. The threshold may be, for example, 10% or 20%. In embodiments, the method may involve diagnosing trisomy 21, trisomy 18, trisomy 13, or another aneuploidy condition. 
         [0019]    In other aspects, the invention provides a method for determining a degree of relatedness between two genomic samples. The method involves obtaining sequence reads from a first genomic sample and a second genomic sample amplified by FAST-SeqS; determining genotype calls at a plurality of SNP loci on the samples, based on the sequence reads; generating a DNA fingerprint for each sample based on the genotype calls; and comparing the DNA fingerprint of the first genomic sample to the DNA fingerprint of the second genomic sample to determine a degree of relatedness between the two samples. In embodiments, the first genomic sample includes a biopsy from an embryo or circulating cell-free fetal DNA. 
         [0020]    In some embodiments of the method, generating a DNA fingerprint involves assigning a numerical score to each SNP locus and concatenating the numerical scores into a string, wherein determining a degree of relatedness involves calculating a distance metric between the DNA fingerprints. DNA fingerprinting includes numerical scores that identify at least two of the following states: heterozygous reference, heterozygous alternate, and homozygous. The method may further involve determining phylogeny based on the calculated distance metric. A degree of relatedness greater than a threshold value may indicate that the samples are identical, whereas a degree of relatedness below a threshold value may indicate the samples are from different sources. In embodiments, the first genomic sample includes DNA from an embryo and the second genomic sample is biopsied from a fetus putatively derived from the embryo. In other embodiments, the first genomic sample comprises DNA from an embryo and the second genomic sample comprises DNA from a sibling embryo. 
         [0021]    Another aspect of the invention provides a method for detecting contamination in a sample. The method involves obtaining sequence reads from a genomic sample amplified by FAST-SeqS; identifying, based on the sequence reads, a characteristic of SNPs present in the genomic sample; comparing the characteristic to an expected characteristic for the genomic sample; and determining, based on the comparison, whether contamination has occurred. 
         [0022]    In embodiments, the characteristic includes genotype calls, allele fractions, or a quantity of non-homozygous SNPs. The genomic sample may include a biopsy from an embryo or circulating cell-free fetal DNA. In certain embodiments of the method, the second determining step is based on whether the comparison reveals the characteristic of SNPs exceeds a threshold. The expected characteristic may be based on a characteristic of a known diploid sample. 
         [0023]    The method may further involve determining a DNA fingerprint of a contaminant based on the comparison and identifying a source of contamination based on the DNA fingerprint. 
         [0024]    In other aspects, the invention provides a method for determining chromosome copy number. The method involves obtaining allele fractions for SNPs sequenced by FAST-SeqS and determining chromosome copy number based on the allele fractions. 
         [0025]    In some embodiments of the method, the genomic sample is biopsied from an embryo. In some embodiments, the genomic sample comprises circulating cell-free fetal DNA, amniotic fluid, chorionic villus, fetal cells in maternal blood, trophoblasts, umbilical cord blood, tumor biopsy, or circulating tumor DNA. 
         [0026]    In embodiments, an allele fraction may indicate a genomic locus is homozygous or that a genomic locus is heterozygous. An allele fraction or set of allele fractions of 100% may indicate monosomy, whereas an allele fraction or set of allele fractions of 50% may indicate disomy. An allele fraction or set of allele fractions between 10% and 40% or between 60 and 90% may indicate trisomy or tetrasomy. 
         [0027]    In some embodiments, the method further involves identifying allele fractions that deviate from an expected allele fraction by more than a threshold amount. The threshold may be, for example, 10% or 20%. In embodiments, the method may involve diagnosing trisomy 21, trisomy 18, trisomy 13, or another aneuploidy condition. 
     
    
     
       BRIEF DESCRIPTION OF THE DRAWINGS 
         [0028]      FIG. 1  shows a flowchart of a method for making copy number calls and detecting errors. 
           [0029]      FIG. 2  shows a flowchart of a method for DNA fingerprinting. 
           [0030]      FIG. 3  shows a flowchart of a method for detecting contamination. 
       
    
    
     DETAILED DESCRIPTION 
       [0031]    The present disclosure is generally directed to validating the results of pre-implantation genetic screening (PGS). One key objective common to PGS and multiple other genetic tests (e.g. cancer tumor sequencing and pre-natal screening) is to accurately determine the copy number of each chromosome. Such an accurate calling of chromosome copy number should enable both the identification of aneuploidy as well as the presence of an unexpected integral multiple of the haploid chromosome count. Types of aneuploidy include monosomy (one copy of a chromosome), trisomy (three copies of a chromosome), and tetrasomy (four copies of a chromosome) and common examples of unexpected integral multiples of the halploid chromosome count include triploidy (three full sets of chromosomes), tetrasomy (four full sets of chromosomes), haploidy (one set of chromosomes), and isodisomic uniparental disomy (two sets of chromosomes, both from one parent). 
         [0032]    Methods of PGS known in the art, such as FAST-SeqS, are useful for detecting chromosomal aneuploidies and other chromosome count abnormalities. But those methods are still subject to errors (false positives and false negatives) and contamination of samples. 
         [0033]    Single-nucleotide polymorphisms (SNPs) sequenced from an embryo grown in vitro or from circulating cell-free fetal DNA (ccffDNA) obtained from a pregnant woman, for example, can be used to provide insights about aneuploidies, other chromosome count abnormalities, and contamination. The SNPs for use with the present invention can come from DNA captured by massively parallel sequencing techniques such as FAST-SeqS. 
         [0034]    The FAST-SeqS method involves capturing fragments from all chromosomes in a sample with a single primer pair. Using a single primer pair streamlines the PGS process. Prior techniques required preparation of whole genome libraries, which involved many complicated and technically challenging steps including, whole genome amplification, DNA fragmentation, end-repair, 5′-phosphorylation, addition of terminal dA nucleotides to 3′ ends, ligation to adapters, PCR amplification, several purification steps, sequencing, and chromosome copy number calling. FAST-SeqS avoids many of those steps by using a single primer pair and a small but effective number of DNA fragments to be assessed, rather than the whole genome. See International Patent Application Publication No. WO 2013148496; and Kinde et al., 2012, “FAST-SeqS: A Simple and Efficient Method for the Detection of Aneuploidy by Massively Parallel Sequencing,” PLOS ONE 7(7):e41162, the entirety of which is incorporated herein by reference. 
         [0035]    Single-nucleotide polymorphisms (SNPs) captured and sequenced by the FAST-SeqS method can be used for a number of applications in PGS. The present disclosure provides uses for the sequenced SNPs including copy number calling and error detection, DNA fingerprinting, and detection of human contamination. As would be understood by a person of skill in the art, the SNP-based approaches described herein can be used for many other genetic screening applications beyond PGS. The methods described herein are useful for cancer screening, forensics, paternity testing, screening for genetic disorders, monitoring cancer treatments, and more. 
         [0000]    a. Copy Number Calling and Error Detection 
         [0036]    FAST-SeqS detects aneuploidies using chromosome copy numbers obtained from sequence reads across a chromosome of interest. However, using sequence reads alone can lead to analytical errors that yield false positive aneuploidy calls (particularly for monosomy, trisomy, and tetrasomy) and ambiguous results with respect to other chromosome count abnormalities (e.g., triploidy, haploidy, and uniparental disomy). 
         [0037]    For example, variable sequence read depths or other analytical irregularities may contribute to a false call of monosomy when the read count data indicate that a particular chromosome has only one copy when compared with the sequence reads of other chromosomes in a sample. Using read counts alone is subject to inaccuracies. However, according to the present disclosure, a monosomy result can be confirmed by assaying SNPs of the chromosome in question. 
         [0038]      FIG. 1  shows a method  100  for validating a putative chromosome copy number call. The method  100  includes a first step  105  of obtaining sequence reads from a genomic sample amplified by FAST-SeqS. The sample may comprise embryonic tissue, ccffDNA, chorionic villus tissue, amniotic fluid, fetal cells in maternal blood, trophoblasts, umbilical cord blood, or any other sample type known in the art for use with prenatal diagnosis. The sample may also comprise tumor DNA or circulating tumor DNA. A second step  109  comprises enumerating read counts from the sequence reads. Then in step  113  putative chromosome copy numbers are calculated based on the read counts. Optionally, a person practicing methods of the invention can begin by obtaining putative chromosome copy numbers for a genomic sample, wherein the copy numbers have been calculated from sequence read counts of FAST-SeqS-amplified DNA performed by another individual. Once putative chromosome copy numbers are obtained, the method continues in step  117  with obtaining allele fractions for SNPs captured by FAST-SeqS sequence reads. 
         [0039]    An allele fraction is the proportion of a particular allele at a locus of interest. It may be expressed as a percentage. For example, a homozygous locus could be said to have an allele fraction of 100%, whereas a diploid locus that is heterozygous could be said to have an allele fraction of 50%. When measuring allele fraction some margin of error may be expected, and so a measured allele fraction of 47%, for example, may still be called a heterozygous diploid locus. However, as discussed in greater detail below, allele fractions that deviate significantly from 100% or 50% may be indicative of aneuploidy. 
         [0040]    The allele fractions and the putative chromosome copy numbers are compared in step  121  to validate the putative chromosome copy numbers. Depending on what type of aneuploidy (or euploidy) is indicated by the putative chromosome copy number data, the validation step may comprise looking at different comparison metrics between the two sets of data. Generally, when an observed allele fraction is inconstant with the putative chromosome copy number, that result invalidates the putative chromosome copy number. 
         [0041]    In one embodiment, a researcher may want to validate a monosomy call indicated by the putative chromosome copy number (i.e., copy number of 1). To detect a false monosomy call in a sample on a chromosome that is actually diploid, a researcher may look for the presence of non-homozygous genotype calls along the chromosome. An allele fraction of 100% would be consistent with monosomy, but the presence of heterozygous SNPs (presence of two alleles) at any genomic loci would reveal a copy number of at least 2. A copy number of 2 would indicate at least disomy. In such a case, the monosomy call based on read counts would prove to be an erroneous result. On the other hand, if the SNPs along the chromosome of interest revealed an apparent loss of heterozygosity, the monosomy call would be confirmed. 
         [0042]    Using similar methods, a false trisomy or tetrasomy call can be detected as well. In a sample where read counts indicate more than two copies of a chromosome (i.e., trisomy or tetrasomy), a researcher can examine allele fractions of heterozygous SNP calls along that chromosome. In the case of a false call, heterozygous call allele fractions would not be statistically different from expectation for a diploid sample, i.e. approximately 50% for each allele. The presence of approximately 50% of each heterozygous allele would indicate that there are in fact two copies of the chromosome. A tolerance threshold can be used, wherein if an allele frequency is between, for example 45% and 55%, it is considered to be present in two copies. Alternatively, the tolerance threshold can be 40% to 60%. 
         [0043]    However, if the allele fractions of heterozygous calls were shifted significantly from that expected for the diploid case, that would be indicative of a true trisomy or tetrasomy if observed in the presence of an elevated copy number measurement based on read count. If the allele frequencies fall outside the tolerance threshold (for example, if one allele is present at 25% and the other is present at 75%), the researcher can conclude aneuploidy exists. 
         [0044]    Triploidy, haploidy, and isodisomic uniparental disomy present different analytical problems for the researcher. Based on read count alone, those abnormalities would appear to be diploid. That is because read count relies on the relative number of reads between chromosomes to identify outliers. Using SNPs, however, can reveal the correct ploidy level of the sample. For example, to detect triploidy (i.e., having 3 times the haploid number of chromosomes, or 3n) in a sample whose read counts yield a putative copy number of 2 for all autosomes, the sample can be assayed for the number of heterozygous SNP calls and, separately, the allele fractions of the heterozygous SNP calls in the sample. If either the number of heterozygous SNPs differs from the expectation for a diploid sample, or if the allele fraction distribution of heterozygous SNP calls differs from an expected allele fraction distribution (i.e., differs significantly from 50%), it can be inferred that the sample is triploid even though the read-based copy number measurement is indicative of diploidy. 
         [0045]    Similarly, one can detect haploidy or isodisomic uniparental disomy (iUPD) in a sample determined to be diploid by read counts alone. The genotypes of a plurality (or preferably all) of callable known SNP loci can be assessed. If the genotypes of the plurality of SNP sites exhibits a loss of heterozygosity, one can infer the presence of haploidy or iUPD in the sample even though the read-based copy number measurement is indicative of diploidy. 
         [0046]    Using the methods described above can confirm or refute a copy number determined by FAST-SeqS alone. The methods allow for more effective identification of chromosomal anomalies such as trisomy 21, trisomy 18, and trisomy 13. 
         [0000]    b. DNA Fingerprinting 
         [0047]    DNA fingerprinting (also known as DNA profiling or DNA typing) is a technique well known in the art, which can be used to identify an individual using their DNA. DNA fingerprinting relies on highly variable sequences that differ from one person to the next. 
         [0048]    The present disclosure provides methods of using genotype calls of SNPs from FAST-SeqS amplified DNA to generate DNA fingerprints to identify samples. The method involves performing FAST-SeqS on the sample and generating genotype calls across multiple loci. As shown in  FIG. 2 , a method  200  of for determining a degree of relatedness using DNA fingerprinting may comprise a first step  205  of obtaining sequence reads from two genomic samples amplified by FAST-SeqS. A sample may comprise an embryo biopsy, ccffDNA, amniotic fluid, and the like. Alternatively it could comprise saliva, blood, a buccal swab, or any other bodily cellular sample, as would be understood by those skilled in the art depending on the particular comparison to be performed. Next in step  209 , genotype calls are determined at a plurality of SNP loci on the samples, based on the sequence reads. A DNA fingerprint is generated in step  213  for each sample based on the genotype calls. The genotype calls can be assigned a digital identifier or a numerical score and concatenated into a string. For example, the digital identifiers can be 0, 1, and 2, corresponding to homozygous reference, homozygous alternate, and heterozygous genotypes, respectively. Alternatively, the digital identifier could be condensed in such a manner that 0 indicates the presence of only the reference allele and 1 indicates the presence of the non-reference allele (homozygous non-reference or heterozygous). 
         [0049]    The concatenated string of genotype calls or digital identifiers constitutes the DNA fingerprint, and can be compared to the DNA fingerprint of another sample, as shown in step  217 , to determine the degree of relatedness or identity. Samples may be determined to be identical if they meet some threshold degree relatedness. Methods for determining a degree of relatedness are known in the art and may include performing clustering on the basis of a distance metric to infer relatedness. 
         [0050]    A fingerprint assigned to a sample can serve as the basis of comparison to fingerprints from other samples to determine the degree of relatedness between them. The fingerprints can determine if two samples are unrelated, related, or identical. In the context of PGS, those fingerprints can be used to determine or rule out that a sample swap has occurred. Sample swaps can occur due to human error, either by the clinic performing the IVF or by the laboratory analyzing the biopsied tissue. 
         [0051]    DNA fingerprinting can also be used to determine phylogenic relationships between samples, including confirming paternity. These samples can be embryo biopsies for PGS, or can be other sample types, such as ccffDNA in maternal blood, donor DNA in allograft recipients, blood or saliva samples from individuals seeking to learn about ancestry or relatedness, and biological samples for forensic applications. 
         [0052]    In the case of determining whether a sample swap has occurred during PGS, all embryos from a given patient should exhibit a degree of relatedness equivalent to that among siblings. Any embryo from such a patient which does not exhibit a similar level of relatedness can therefore be identified as a swap. Similarly, if a sample of biological fluid or tissue is obtained from the mother, FAST-SeqS can be performed on that sample to determine the fingerprint of the mother. Using this information, it is possible to identify a gross mislabeling of all embryos from a given IVF procedure by determining their relatedness to the fingerprint derived from her sample. 
         [0053]    In addition, it is possible to compare the FAST-SeqS fingerprint of a tested embryo before implantation to the fingerprint of a fetus, child, or product of conception supposedly derived from the embryo. That way, one could check to ensure that the chosen embryo is indeed the one that was transferred. The procedure would be done in the same manner as noted above, except rather than comparing DNA fingerprints of two embryo samples to each other, the fingerprint of an embryo would be compared to that of the alternative sample type with the expectation that the fingerprints would be identical if the correct embryo was indeed utilized. 
         [0000]    c. Detection of Human Contamination 
         [0054]    Human contamination in a sample being analyzed by the FAST-SeqS method can also be identified using SNPs. As would be recognized by a person skilled in the art, allele fractions for homozygous and heterozygous calls should conform to a specific expected distribution. If the distribution of allele fractions for any given sample deviates from that expectation, it can be inferred that sample contamination has occurred. It may even be possible to back out the actual fingerprint of the contaminating sample, based on the particular shift for each locus. Accordingly, one can identify the source of contamination. 
         [0055]    Additionally, the number of heterozygous SNPs can be used to evaluate whether contamination exists. If the number of heterozygous loci is particularly large for a sample, multiple samples may have been simultaneously amplified. The number of heterozygous loci is considered large when compared to the numbers empirically observed for samples known not to be contaminated. 
         [0056]      FIG. 3  shows a method  300  for detecting contamination in a sample in accordance with the present disclosure. The method  300  includes the first step  305  of obtaining sequence reads from a genomic sample amplified by FAST-SeqS technology. The sample may comprise embryonic tissue, ccffDNA, chorionic villus tissue, amniotic fluid, fetal cells in maternal blood, trophoblasts, umbilical cord blood, or any other sample type known in the art for use with prenatal diagnosis. The sample may also comprise tumor DNA or circulating tumor DNA. Next, in step  309 , a characteristic of SNPs in the genomic sample is identified from the sequence reads. The characteristic can be genotype calls across multiple SNP loci. It can also be allele fractions at one or more SNP loci. Alternatively, the characteristic can be a quantity of non-homozygous SNPs in the sample. In some embodiments, only one of those characteristics is used. In other embodiments, multiple are used. Using multiple characteristics may increase the reliability of the result. Other similar characteristics that are known in the art can also be used. 
         [0057]    The method  300  includes a step  313  of comparing the characteristic identified in step  309  to an expected characteristic for a non-contaminated genomic sample. For example, a practitioner of the method  300  may make a comparison to the expected genotype calls for a known diploid sample or set of diploid samples. The expected characteristic can be any of the characteristics described above that were identified in step  309 . The comparison helps determine in step  313  whether the sample is an outlier and therefore contamination has occurred. That determination can be based on whether the comparison shows that the characteristic measured in the SNPs exceeds some threshold. 
         [0058]    Optionally, if a sample is determined to be an outlier, the method  300  may comprise deducing the fingerprint of the contaminating moiety by “backing out” its genotype based on the direction of shift away from expectation for each SNP or other polymorphic locus. 
       Incorporation by Reference 
       [0059]    References and citations to other documents, such as patents, patent applications, patent publications, journals, books, papers, web contents, have been made throughout this disclosure. All such documents are hereby incorporated herein by reference in their entirety for all purposes. 
       Equivalents 
       [0060]    Various modifications of the invention and many further embodiments thereof, in addition to those shown and described herein, will become apparent to those skilled in the art from the full contents of this document, including references to the scientific and patent literature cited herein. The subject matter herein contains important information, exemplification and guidance that can be adapted to the practice of this invention in its various embodiments and equivalents thereof.